| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific... |
| 23 Sep 2026 |
8-K: Other Events
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage... |
| 20 Jul 2026 |
8-K: Regulation FD Disclosure
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 |
| 20 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter agreement (this “Agreement”) is intended to confirm our mutual agreement with respect to your continued employment with Armata Pharmaceuticals, Inc. (the “Company”) from and after the date hereof. |
| 13 Jul 2026 |
8-K: Regulation FD Disclosure
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia |
| 23 Jun 2026 |
8-K: Other Events
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 |
| 16 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Shareholders held on June 11, 2026 (the “Meeting”), the shareholders of Armata Pharmaceuticals, Inc. (the “Company”) elected seven members to our board of directors, each for a one-year term expiring at the annua... |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Credit and Security Agreement, dated as of May 12, 2026, by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto (togethe... |
| 07 May 2026 |
8-K: Regulation FD Disclosure
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development |
| 27 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
LOS ANGELES, Calif., April 27, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage... |
| 02 Apr 2026 |
8-K: Other Events
Armata Pharmaceuticals, Inc. (“Armata” or the “Company”) has set June 11, 2026 as the date for its 2026 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting will be held at 8:30 a.m. (Pacific Time), at the Company’s ... |
| 25 Mar 2026 |
8-K: Results of Operations and Financial Condition
LOS ANGELES, California, March 25, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacterioph... |
| 19 Mar 2026 |
8-K: Regulation FD Disclosure
LOS ANGELES, California, March 19, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacterioph... |
| 23 Feb 2026 |
8-K: Regulation FD Disclosure
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus |
| 26 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
FIFTH AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT, dated as of January 23, 2026 (this “Amendment”), by and among Armata Pharmaceuticals, Inc., a Washington corporation (the “Borrower”), each Guarantor from time to time... |
| 13 Jan 2026 |
8-K: Regulation FD Disclosure
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia |
| 01 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows: |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
LOS ANGELES, California, November 12, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophag... |
Loading...